Orserdu
Total Payments
$6.1M
Transactions
13,117
Doctors
5,554
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.4M | 5,732 | 3,307 |
| 2023 | $3.7M | 7,385 | 3,834 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.7M | 545 | 61.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 386 | 22.6% |
| Consulting Fee | $388,212 | 217 | 6.4% |
| Food and Beverage | $363,523 | 11,368 | 6.0% |
| Travel and Lodging | $220,433 | 517 | 3.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $15,400 | 4 | 0.3% |
| Honoraria | $9,476 | 61 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $2,500 | 1 | 0.0% |
| Education | $96.50 | 18 | 0.0% |
Payments by Type
Research
$3.7M
545 transactions
General
$2.4M
12,572 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| STML-IST-QLHC | Stemline Therapeutics Inc. | $1.7M | 0 |
| EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | Stemline Therapeutics Inc. | $1.1M | 0 |
| Tagraxofusp (SL-401) in Patients With CMML or MF | Stemline Therapeutics Inc. | $643,221 | 0 |
| Dana Farber Cancer Institute | Stemline Therapeutics Inc. | $170,359 | 0 |
| A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer, Interventional | Stemline Therapeutics Inc. | $151,300 | 3 |
Top Doctors Receiving Payments for Orserdu — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Cleveland, OH | $8,692 | 6 |
| , N.P | Nurse Practitioner | Dallas, TX | $8,195 | 37 |
| , M.D | Internal Medicine | Palo Alto, CA | $7,775 | 8 |
| , M.D | Hematology & Oncology | Atlanta, GA | $7,125 | 9 |
| , M.D | Internal Medicine | Lone Tree, CO | $7,124 | 8 |
| , MD | Medical Oncology | Middleton, WI | $6,977 | 6 |
| , M.D., PH.D | Internal Medicine | Santa Monica, CA | $6,263 | 21 |
| , M.D | Hematology & Oncology | Fort Worth, TX | $6,106 | 16 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $5,971 | 3 |
| , MD,PHD | Hematology & Oncology | Boston, MA | $5,809 | 6 |
| Komal Jhaveri | Internal Medicine | New York, NY | $5,802 | 7 |
| , M.D | Internal Medicine | Dallas, TX | $5,033 | 7 |
| , M.D | Medical Oncology | Stanford, CA | $4,583 | 3 |
| , M.D | Medical Oncology | San Antonio, TX | $4,510 | 2 |
| , M.D | Hematology | Hackensack, NJ | $4,284 | 3 |
| Miki Haraguni | Family | Westlake Village, CA | $4,081 | 9 |
| , MD | Hematology & Oncology | Gilbert, AZ | $3,724 | 2 |
| , MD | Specialist | Pittsburgh, PA | $3,654 | 4 |
| , MD | Medical Oncology | Charlotte, NC | $3,523 | 3 |
| , M.D | Internal Medicine | Glen Allen, VA | $3,509 | 2 |
| , MD | Hematology & Oncology | Boston, MA | $3,400 | 5 |
| , M.D | Medical Oncology | Houston, TX | $3,200 | 5 |
| , M.D | Internal Medicine | Boston, MA | $2,720 | 4 |
| , MD | Hematology & Oncology | Saint James, NY | $2,517 | 2 |
| Rebecca Nelson | Family | Tampa, FL | $2,337 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 5,554
- Transactions 13,117
About Orserdu
Orserdu is a drug associated with $6.1M in payments to 5,554 healthcare providers, recorded across 13,117 transactions in the CMS Open Payments database. The primary manufacturer is Stemline Therapeutics Inc..
Payment data is available from 2023 to 2024. In 2024, $2.4M was paid across 5,732 transactions to 3,307 doctors.
The most common payment nature for Orserdu is "Unspecified" ($3.7M, 61.0% of total).
Orserdu is associated with 5 research studies, including "STML-IST-QLHC" ($1.7M).